Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain scan breakthrough: new tracer could catch Parkinson's early

NCT ID NCT06738862

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested a new radioactive tracer called [18F] - FD17 for PET imaging to detect clumps of a protein called alpha-synuclein in the brain. These clumps are linked to Parkinson's disease, multiple system atrophy, and a sleep disorder that often precedes Parkinson's. Researchers scanned 55 people, including healthy volunteers and patients, to see if the tracer could help diagnose these conditions earlier and more accurately. The goal is to improve early detection and diagnosis of neurodegenerative diseases.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[18F] - FD17 (a radioactive imaging agent used in PET scans)
What this could lead to
If successful, this imaging method could allow doctors to detect Parkinson's and related diseases earlier and more accurately, potentially before symptoms worsen.
What could go wrong
This is a small, completed imaging study, not a treatment trial. The agent may not reliably distinguish between different diseases, and further larger studies are needed to confirm its usefulness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

55 people

The number who actually took part.

Started

Dec 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

10 PD subjects ,10 MSA subjects, 10 RBD subjects ,and 5 healthy control subjects

Ages

45 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1: Normal cognitive function, CDR score=0(for healthy subjects) 2: Without neurological disorders, major chronic diseases, malignant tumors, or acute infectious diseases (for healthy subjects) 3: Without the family history of neurological disorders related to motor or cognitive impairments(for healthy subjects) 4: Clinical diagnosis of idiopathic PD (for PD patients) 5: Clinical diagnosis of MSA (for MSA patients) 6: Clinical diagnosis of idiopathic RBD (for RBD patients) 7: An informed consent form signed in writing by the subject or their legal guardian or caregiver. 8: Must be abled to be accompanied by nursing staff 9: Must be able to understand and sign a informed consent form before any evaluation and examination 10: Must have medical records to prove that they have undergone surgical sterilization (such as hysterectomy, bilateral oophorectomy, or tubal ligation) or menopause for more than one year.(for female subjects) 11: Must adopt isolation contraception measures within 3 months after the start of this study.(for female subjects) 12: Willing and capable to cooperate with all projects of this study. Exclusion Criteria: * 1: Other severe neurological disorders. Gastrointestinal, cardiovascular, liver, kidney, hematological, tumor, endocrine, respiratory, immunodeficiency, and other serious diseases. 2: Received ionizing radiation outside the scope of this experiment, resulting in an annual radiation exposure dose exceeding 50 mSv in the past year, 3: History of drug abuse or alcoholism 4: Pregnant or lactating women 5: Poor venous conditions, unable to tolerate repeated venipuncture 6: Received experimental drug or device treatment with unclear efficacy or safety in last 1 month. 7: Any situation that the investigators believe may cause harm or potential harm in any aspect related to this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple system atrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.